Clinical Trial Update: Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating glutamatergic modulation to facilitate behavioral treatment for Cocaine Use Disorder is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cocaine Use Disorder

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Cocaine Use Disorder | Phase 3 | Status: SUSPENDED